Marked Response to Icotinib in Lung Squamous Cell Carcinoma with EGFR Wild-Type.
We present a case of a 72-year male with primary lung squamous cell carcinoma without an epidermal growth factor receptor (EGFR) gene mutation that exhibited a lasting efficacy to icotinib treatment. Originally, the patient was treated with GP regimen for 2 cycles, local lesion radiotherapy (DT46Gy/2Gy*23F), and TP regimen for 2 cycles, with efficacy evaluation as stable disease (SD). The condition was stable for 10 months until the fifth lumbar metastasis was discovered by emission computed tomography (ECT) in July 2015, and the pulmonary metastasis increased. Icotinib was administered at 125 mg orally three times per day. Chest computed tomography (CT) scan showed the tumor was in partial response (PR) and the PR lasted for 27 months.